Add time:08/05/2019         Source:sciencedirect.com

To analyse the coronary effects of endothelin-1 after ischemia–reperfusion, the left anterior descending coronary artery of anesthetized pigs was subjected to 30-min occlusion followed by 60-min reperfusion. Then, rings distal (ischemic arteries) and proximal (control arteries) to the occlusion were taken from this artery and prepared for isometric tension recording. The sensitivity of the contraction in response to endothelin-1 (3 × 10− 10–3 × 10− 7 M) and the endothelin ETB receptor agonist IRL-1620 (3 × 10− 10–3 × 10− 7 M) was greater in ischemic vessels. The endothelin ETA receptor antagonist BQ-123 (10− 7–3 × 10− 6 M) decreased the sensitivity of the response to endothelin-1 similarly in ischemic and control arteries. The endothelin ETB receptor antagonist BQ-788 (10− 6 M), endothelium removal or the inhibitor of nitric oxide synthesis Nω-nitro-L-arginine methyl ester (L-NAME 10− 4 M) potentiated the response to endothelin-1 and IRL-1620 in control arteries only. The cyclooxygenase inhibitor meclofenamate (10− 5 M) augmented the maximal response to endothelin-1 in control arteries, and reduced it in ischemic arteries. In precontracted arteries, IRL-1620 (3 × 10− 11–3 × 10− 10 M) relaxed control but not ischemic arteries, and L-NAME or meclofenamate abolished this relaxation. Therefore, ischemia–reperfusion increases the coronary vasoconstriction in response to endothelin-1 probably due to impairment of endothelin ETB receptor-induced release of nitric oxide and prostacyclin, augmentation of the contractile response to activation of endothelin ETB receptors, and increased release of vasoconstrictor prostanoids.

We also recommend Trading Suppliers and Manufacturers of endothelin, Nle(7)- (cas 134699-39-1). Pls Click Website Link as below: cas 134699-39-1 suppliers